Share Prices & Company Research

Market News

27 Oct 2021 | 12:05

Glaxo upgrades FY EPS guidance after strong Q3

(Sharecast News) - GlaxoSmithKline upgraded its full-year earnings per share guidance on Wednesday as it posted a jump in third-quarter sales. The pharmaceuticals group said Q3 sales rose 10% at constant exchange rates to £9.1bn. This was driven by strong growth in new specialty products, partly offset by a decline in the established pharmaceuticals portfolio.

Sales in the pharmaceuticals segment grew 10% to £4.4bn, while vaccine sales were 13% higher at £2.2bn, driven by sales of shingles vaccines Shingrix - up 41% to £502m - and pandemic adjuvant sales.

Glaxo said sales of Xevudy, the monoclonal antibody treatment for Covid-19, came in at £114m and contributed around three percentage points to total pharmaceuticals growth in the quarter. Meanwhile, the consumer healthcare division saw an 8% increase in sales to £2.5bn.

Chief executive officer Emma Walmsley said: "GSK has delivered another quarter of strong business performance, with double-digit sales growth in pharmaceuticals and vaccines, increased momentum in consumer healthcare, and continued discipline on costs.

"This has allowed us to improve our full-year guidance and, alongside the progress in strengthening our R&D pipeline, reinforces our confidence in the outlook for a step-change in growth and performance in 2022 and beyond. We also continue to make excellent progress towards unlocking the value of consumer healthcare through a successful demerger in mid-2022."

Glaxo now expects 2021 adjusted EPS to drop by between 2% and 4% at constant exchanges rates, excluding Covid-19 solutions, compared to previous guidance for a mid-to-high single-digit decline. The company reaffirmed its expectations for "meaningful improvement in revenues and margins" in 2022.

At 1220 BST, the shares were up 2.1% at 1,464.60p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.